Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance

Steckbeck, Jonathan D.; Grieser, Heather; Sturgeon, Timothy J.; Taber, Rachel; Chow, Andrew; Bruno, JoAnne; Murphy-Corb, Michael; Montelaro, Ronald C.; Cole, Kelly Stefano

doi:10.1111/j.1600-0684.2006.00173.x

Cited by 13 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4). Serum samples were diluted, polyclonal IgG was captured, and binding experiments were carried out as previously described with minor modifications (30)(31)(32). Sensograms demonstrating the specifics of the binding response for the ferret sera are shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Sequential Seasonal H1N1 Influenza Virus Infections Protect Ferrets against Novel 2009 H1N1 Influenza Virus

Carter

Bloom

Nascimento

et al. 2013

J Virol

View full text Add to dashboard Cite

d Individuals <60 years of age had the lowest incidence of infection, with ϳ25% of these people having preexisting, cross-reactive antibodies to novel 2009 H1N1 influenza. Many people >60 years old also had preexisting antibodies to novel H1N1. These observations are puzzling because the seasonal H1N1 viruses circulating during the last 60 years were not antigenically similar to novel H1N1. We therefore hypothesized that a sequence of exposures to antigenically different seasonal H1N1 viruses can elicit an antibody response that protects against novel 2009 H1N1. Ferrets were preinfected with seasonal H1N1 viruses and assessed for cross-reactive antibodies to novel H1N1. Serum from infected ferrets was assayed for cross-reactivity to both seasonal and novel 2009 H1N1 strains. These results were compared to those of ferrets that were sequentially infected with H1N1 viruses isolated prior to 1957 or more-recently isolated viruses. Following seroconversion, ferrets were challenged with novel H1N1 influenza virus and assessed for viral titers in the nasal wash, morbidity, and mortality. There was no hemagglutination inhibition (HAI) cross-reactivity in ferrets infected with any single seasonal H1N1 influenza viruses, with limited protection to challenge. However, sequential H1N1 influenza infections reduced the incidence of disease and elicited cross-reactive antibodies to novel H1N1 isolates. The amount and duration of virus shedding and the frequency of transmission following novel H1N1 challenge were reduced. Exposure to multiple seasonal H1N1 influenza viruses, and not to any single H1N1 influenza virus, elicits a breadth of antibodies that neutralize novel H1N1 even though the host was never exposed to the novel H1N1 influenza viruses.

show abstract

Section: Resultsmentioning

confidence: 99%

Sequential Seasonal H1N1 Influenza Virus Infections Protect Ferrets against Novel 2009 H1N1 Influenza Virus

Carter

Bloom

Nascimento

et al. 2013

J Virol

View full text Add to dashboard Cite

show abstract

“…Users overwhelmingly preferred to immobilize the ligand via amine coupling (96%), although a few groups used thiol coupling (3%) or developed novel immobilization chemistries [e.g., Reference 717]. In capturing assays, ligands were most often tagged with biotin (63%), His x (10%), or GST (8%), although several authors captured using anti-IgG [353,364,372], protein A, G, or A/G [217,294,388,474,487,542,557], or ligand-specific antibodies [252,558,561]. Clark et al [143] and Le Pogam et al [919] minimally biotinylated proteins for streptavidin capture and Zaman et al [943] blocked a target's active site with a small-molecule binder during immobilization to ensure the target was not coupled via this site [943].…”

Section: Immobilization Methodsmentioning

confidence: 99%

Survey of the year 2006 commercial optical biosensor literature

Rich

Myszka

2007

J of Molecular Recognition

109

View full text Add to dashboard Cite

We identified 1219 articles published in 2006 that described work performed using commercial optical biosensor platforms. It is interesting to witness how the biosensor market is maturing with an increased number of instrument manufacturers offering a wider variety of platforms. However, it is clear from a review of the results presented that the advances in technology are outpacing the skill level of the average biosensor user. While we can track a gradual improvement in the quality of the published work, we clearly have a long way to go before we capitalize on the full potential of biosensor technology. To illustrate what is right with the biosensor literature, we highlight the work of 10 groups who have their eye on the ball. To help out the rest of us who have the lights on but nobody home, we use the literature to address common myths about biosensor technology.

show abstract

“…In an effort to translate our findings with MAb binding kinetics to the study of polyclonal serum antibody responses generated in rhesus macaques infected with attenuated SIV, we analyzed the quantitative and qualitative binding properties of well-characterized, longitudinal serum samples to trimeric, recombinant SIV/17E-CL gp140 envelope proteins using SPR (35). We initiated this study in an attempt to identify a reliable measure of the strength of antibody binding without resorting to treatment with 8 M urea as in the avidity ELISA, thus removing the potential limitations involved in measuring binding stability under partially denaturing conditions.…”

Section: The Polyclonal Antibody Response To Siv Infection Undergoes mentioning

confidence: 99%

Dissecting the Humoral Immune Response to Simian Immunodeficiency Virus: Mechanisms of Antibody-Mediated Virus Neutralization

Steckbeck

Cole

2006

View full text Add to dashboard Cite

The ultimate goal of an AIDS vaccine is to elicit potent cellular and humoral immune responses that will result in broadly enduring protective immunity. During the past several years, we have focused on characterizing the quantitative and qualitative properties of the antibody response, principally working to define the mechanism(s) of antibody-mediated neutralization in vitro. We have utilized a panel of monoclonal antibodies generated from monkeys infected with attenuated SIV for more than 8 mo to dissect the early events of virus infection involved in antibodymediated neutralization. Presented herein are highlights from our studies that have identified potential mechanisms by which antibodies neutralize SIV in vitro.

show abstract

Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance

Cited by 13 publications

References 48 publications

Sequential Seasonal H1N1 Influenza Virus Infections Protect Ferrets against Novel 2009 H1N1 Influenza Virus

Sequential Seasonal H1N1 Influenza Virus Infections Protect Ferrets against Novel 2009 H1N1 Influenza Virus

Survey of the year 2006 commercial optical biosensor literature

Dissecting the Humoral Immune Response to Simian Immunodeficiency Virus: Mechanisms of Antibody-Mediated Virus Neutralization

Contact Info

Product

Resources

About